Gossamer Bio is a San Diego biopharmaceutical company developing seralutinib, an inhaled drug for pulmonary hypertension. GOSS reports earnings on Wed, Nov 4, 2026. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 15 | Chardan Capital | Maintained | Buy | |
| Oct 13 | Chardan Capital | Initiated | Buy | |
| Sep 21 | HC Wainwright & Co. | Target raised | Buy | |
| Aug 14 | Piper Sandler | Maintained | Buy | |
| Jun 25 | HC Wainwright & Co. | Maintained | Buy |
Seasonality
How GOSS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2019.
Whale Options Flow
90DNo whale options trades in GOSS in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether GOSS is in one of them and how their past GOSS trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered GOSS in an article yet. Here's the latest on the wider market.
About Gossamer Bio
Gossamer Bio is a biopharmaceutical company based in San Diego, California. It is developing seralutinib, an investigational inhaled medicine for pulmonary arterial hypertension and for pulmonary hypertension linked to interstitial lung disease. The drug is still in clinical trials and is not yet approved for sale. The company works with Chiesi on development and potential commercialization, and it focuses on people living with pulmonary hypertension.
- Headquarters
- San Diego, CA